SG11202002665UA - Anti-trkb monoclonal antibodies and methods of use - Google Patents
Anti-trkb monoclonal antibodies and methods of useInfo
- Publication number
- SG11202002665UA SG11202002665UA SG11202002665UA SG11202002665UA SG11202002665UA SG 11202002665U A SG11202002665U A SG 11202002665UA SG 11202002665U A SG11202002665U A SG 11202002665UA SG 11202002665U A SG11202002665U A SG 11202002665UA SG 11202002665U A SG11202002665U A SG 11202002665UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- monoclonal antibodies
- trkb monoclonal
- trkb
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592657P | 2017-11-30 | 2017-11-30 | |
| PCT/US2018/062863 WO2019108662A1 (en) | 2017-11-30 | 2018-11-28 | Anti-trkb monoclonal antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002665UA true SG11202002665UA (en) | 2020-04-29 |
Family
ID=64665125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002665UA SG11202002665UA (en) | 2017-11-30 | 2018-11-28 | Anti-trkb monoclonal antibodies and methods of use |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11066474B2 (https=) |
| EP (1) | EP3717514A1 (https=) |
| JP (2) | JP7438937B2 (https=) |
| KR (1) | KR20200090779A (https=) |
| CN (2) | CN111372949B (https=) |
| AU (3) | AU2018375340B2 (https=) |
| BR (1) | BR112020006976A2 (https=) |
| CA (1) | CA3083452A1 (https=) |
| CL (3) | CL2020000855A1 (https=) |
| CO (1) | CO2020004075A2 (https=) |
| EA (1) | EA202090966A1 (https=) |
| IL (1) | IL273538B2 (https=) |
| MA (1) | MA51207A (https=) |
| MX (3) | MX2020003550A (https=) |
| MY (1) | MY203247A (https=) |
| PH (1) | PH12020550409A1 (https=) |
| SG (1) | SG11202002665UA (https=) |
| WO (1) | WO2019108662A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
| WO2019108662A1 (en) * | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
| IL310006A (en) * | 2017-11-30 | 2024-03-01 | Regeneron Pharma | Non-human animals containing a humanized TRKB locus |
| JP7524158B2 (ja) * | 2019-03-04 | 2024-07-29 | 公益財団法人東京都医学総合研究所 | Ｔｒｋ断片をコードする核酸構築物、及びその利用 |
| US12559560B2 (en) * | 2020-01-30 | 2026-02-24 | Fred Hutchinson Cancer Center | Antibody-based compositions for targeting tropomyosin receptor kinase B (TrkB) isoforms |
| WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
| TW202342494A (zh) | 2022-03-30 | 2023-11-01 | 日商肽夢想股份有限公司 | 具有TrkB結合活性之肽複合物 |
| CN120665203B (zh) * | 2025-06-18 | 2026-03-27 | 广东优赛生物医药科技有限公司 | 一种药物组合物及其在治疗中枢性肥胖中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US6225282B1 (en) | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2006133164A2 (en) | 2005-06-06 | 2006-12-14 | Wyeth | Anti-trkb monoclonal antibodies and uses thereof |
| EP1988923A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist |
| EP1988920A1 (en) | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| WO2008058127A2 (en) | 2006-11-09 | 2008-05-15 | Irm Llc | Agonist trkb antibodies and uses thereof |
| CA2672750A1 (en) * | 2006-12-20 | 2008-07-03 | Rinat Neuroscience Corporation | Trkb agonists for treating autoimmune disorders |
| WO2009048605A1 (en) | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| CA2712298C (en) | 2008-01-17 | 2015-11-24 | Irm Llc | Improved anti-trkb antibodies |
| WO2010086828A2 (en) * | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
| WO2011103667A1 (en) | 2010-02-26 | 2011-09-01 | 6452728 Canada Inc. | Agonistic antibodies to trkb receptors and uses thereof |
| GB2491106A (en) | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
| US10080745B2 (en) | 2013-11-25 | 2018-09-25 | The Regents Of The University Of California Santa Cruz | Piericidin bacterial inhibitors |
| ES2936810T3 (es) | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
| CA2993645A1 (en) | 2015-07-28 | 2017-02-02 | Otonomy, Inc. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
| CA3005491A1 (en) | 2015-11-17 | 2017-05-26 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
| JP2019517787A (ja) * | 2016-05-03 | 2019-06-27 | ザ スクリプス リサーチ インスティテュート | 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体 |
| US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
| EP4095161A1 (en) * | 2017-03-15 | 2022-11-30 | Tsinghua University | Novel anti-trkb antibodies |
| WO2019108662A1 (en) * | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
-
2018
- 2018-11-28 WO PCT/US2018/062863 patent/WO2019108662A1/en not_active Ceased
- 2018-11-28 AU AU2018375340A patent/AU2018375340B2/en active Active
- 2018-11-28 CA CA3083452A patent/CA3083452A1/en active Pending
- 2018-11-28 MY MYPI2020001663A patent/MY203247A/en unknown
- 2018-11-28 MX MX2020003550A patent/MX2020003550A/es unknown
- 2018-11-28 SG SG11202002665UA patent/SG11202002665UA/en unknown
- 2018-11-28 MA MA051207A patent/MA51207A/fr unknown
- 2018-11-28 CN CN201880069154.2A patent/CN111372949B/zh active Active
- 2018-11-28 BR BR112020006976-0A patent/BR112020006976A2/pt unknown
- 2018-11-28 PH PH1/2020/550409A patent/PH12020550409A1/en unknown
- 2018-11-28 CN CN202511361457.XA patent/CN121181700A/zh active Pending
- 2018-11-28 EA EA202090966A patent/EA202090966A1/ru unknown
- 2018-11-28 IL IL273538A patent/IL273538B2/en unknown
- 2018-11-28 EP EP18819293.4A patent/EP3717514A1/en active Pending
- 2018-11-28 JP JP2020517858A patent/JP7438937B2/ja active Active
- 2018-11-28 US US16/202,881 patent/US11066474B2/en active Active
- 2018-11-28 KR KR1020207014791A patent/KR20200090779A/ko active Pending
-
2020
- 2020-03-31 CL CL2020000855A patent/CL2020000855A1/es unknown
- 2020-06-03 CO CONC2020/0004075A patent/CO2020004075A2/es unknown
- 2020-07-13 MX MX2025001445A patent/MX2025001445A/es unknown
- 2020-07-13 MX MX2025001444A patent/MX2025001444A/es unknown
-
2021
- 2021-06-09 US US17/342,749 patent/US12037401B2/en active Active
-
2023
- 2023-11-09 JP JP2023191236A patent/JP2024016204A/ja active Pending
-
2024
- 2024-06-07 US US18/737,782 patent/US20240309100A1/en active Pending
- 2024-08-30 CL CL2024002612A patent/CL2024002612A1/es unknown
- 2024-08-30 CL CL2024002614A patent/CL2024002614A1/es unknown
-
2026
- 2026-01-28 AU AU2026200583A patent/AU2026200583A1/en active Pending
- 2026-01-28 AU AU2026200616A patent/AU2026200616A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276731A (en) | Antibodies against CD73 and methods of using them | |
| IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
| ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL279053A (en) | Bispecific anti-PVRIG/ anti-TIGIT antibodies and methods of use | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| IL278772A (en) | Antibodies against 40-OX and methods of use | |
| SI3618863T1 (sl) | Protitelesa proti tigitu in načini uporabe njih | |
| ZA202300348B (en) | Anti-sortilin antibodies and methods of use thereof | |
| IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
| IL275070A (en) | FCRN antibodies and methods of using them | |
| IL273538A (en) | Anti-TRKB Monoclonal Antibodies and Methods of Use | |
| SG11201707886WA (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| IL254951A0 (en) | Monoclonal antibodies of influenza of human origin and methods of using them | |
| IL277212A (en) | Anti-KLK5 antibodies and methods of use | |
| IL280338A (en) | Anti-SIGLEC-5 antibodies and methods of using them | |
| IL274221A (en) | Antibodies to ANTI-APOC3 and methods of use | |
| IL268568A (en) | TRAILshort antibody and methods of use | |
| IL283884A (en) | Antibodies against il-36 and methods of using them | |
| IL279227A (en) | Anti-SIGLEC-7 antibodies and methods of using them | |
| ZA201805051B (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
| ZA202002144B (en) | Antibodies and methods of use | |
| HK40029599A (en) | Anti-trkb monoclonal antibodies and methods of use |